Biosimilars versus biologics: Is marketing madness on the way as biosimilar approvals balloon?

As copycats of complex biologic meds begin to swell into the market and look to unseat their original biologic counterparts, what does that mean for marketing? Will big ad-spending biologic drugmakers drop out of DTC marketing—and will biosimilars sweep in?